{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-066057","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2023-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.638036+00:00","generated_at":"2026-06-14T11:25:51.557527+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Annual meeting results: Patel elected, compensation and auditor approved","bullets":["Elected Dinesh V. Patel as Class I director with 32,660,198 for, 8,874,076 withheld, 3,298,693 broker non-votes.","Advisory executive compensation approved: 39,838,516 for, 1,673,050 against, 22,708 abstentions, 3,298,693 broker non-votes.","Ratified Ernst & Young as independent auditor for FY2023: 44,807,871 for, 15,794 against, 9,302 abstentions."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-066057","json":"https://secwatch.observer/filing/0001104659-23-066057.json","markdown":"https://secwatch.observer/filing/0001104659-23-066057.md","text":"https://secwatch.observer/filing/0001104659-23-066057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923066057/0001104659-23-066057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923066057/tm2317329d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T11:25:51.557527+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"24e7603d54e492ed53068ac5964282cf51c4b7c4","claim":"Protagonist Therapeutics, Inc shareholders approved To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-05-25 meeting.","evidence_excerpt":"Proposal 3 — To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. This proposal was approved by the requisite vote, with the votes thereon as follows: Final Voting Results For Against Abstentions Broker Non-Votes 44,807,871 15,794 9,302 --","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923066057/0001104659-23-066057-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-25"}],"fact_type":"shareholder_vote"},{"claim_id":"a8fb6dd3e58d69f72a460617e99d1687a1dec088","claim":"Protagonist Therapeutics, Inc shareholders approved To approve, on an advisory basis, the compensation of the Company’s named executive officers. at the 2023-05-25 meeting.","evidence_excerpt":"Proposal 2 — To approve, on an advisory basis, the compensation of the Company’s named executive officers. This proposal was approved by the requisite vote, with the votes thereon as follows: Final Voting Results For Against Abstentions Broker Non-Votes 39,838,516 1,673,050 22,708 3,298,693","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923066057/0001104659-23-066057-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-25"}],"fact_type":"shareholder_vote"},{"claim_id":"b3370fe198e684c2f9abe01f1f4c68b2281099c2","claim":"Protagonist Therapeutics, Inc shareholders approved Election of Class I director nominee Dinesh V. Patel at the 2023-05-25 meeting.","evidence_excerpt":"Proposal 1 — To elect the Class I director nominee named below to serve until the 2026 Annual Meeting of Stockholders and until his successor has been duly elected and qualified. Dr. Dinesh V. Patel was elected, with the votes thereon as follows: Final Voting Results Nominee For Withheld Broker Non-Votes Dinesh V. Patel, Ph.D. 32,660,198 8,874,076 3,298,693","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923066057/0001104659-23-066057-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-25"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}